The developing trend of monoclonal antibodies in the treatment of colorectal cancer

Abstract

Monoclonal antibodies (mAbs) against growth factors, receptors and tumor-specific/tumor-selective antigens represent a rapidly growing class of pharmaceutical agents which are poised to make a major impact on the treatment of colorectal cancer. mAbs targeting the epidermal growth factor receptor and the vascular endothelial growth factor have already been approved for the treatment of metastatic colorectal cancer. Other antibodies to the same and other molecular targets implicated in tumor growth and metastasis are undergoing intense preclinical and clinical evaluation. In both the neoadjuvant and adjuvant clinical settings, although mAbs are typically administered in combination with established cytotoxic chemotherapy regimens given their synergistic effect, several agents have demonstrated efficacy when given as monotherapy. At the same time, combination therapies with multiple targeted biological agents are actively being investigated. Existing clinical data and recent progress in preclinical and clinical studies of mAbs are reviewed.

Keywords::

• targeted biologic therapy
• monoclonal antibodies
• colorectal cancer
• epidermal growth factor receptor
• EGFR
• vascular endothelial growth factor
• VEGF
• VEGF-r
• VEGF-Trap
• cetuximab
• erbitux
• panitumumab
• vectibix
• bevacizumab
• Avastin
• matuzumab
• EMD 72000
• nimotuzumab
• TheraCIM h-R3